BioInvent International AB Announces that its CFO will Retire in 2027
BioInvent International AB ("BioInvent") (STO:BINV) , a leader in the discovery of novel immunomodulatory antibodies, today announced that the company's CFO, Stefan Ericsson, has decided to retire when he turns 64 in January 2027. The process of appointing a successor will begin immediately. "On behalf of everyone at BioInvent, I would like to extend our sincere thanks to Stefan for nearly 30 years of outstanding service. He has been a pillar of...
Read more








